[1] Jagdish RK, Maras JS, Sarin SK. Albumin in advanced liver diseases: The good and bad of a drug. Hepatology, 2021, 74(5): 2848-2862.
[2] Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol, 2013, 59(5): 918-920.
[3] European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[4] Gines P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet, 2021, 398(10308): 1359-1376.
[5] Thevenot T, Bureau C, Oberti F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol, 2015, 62(4): 822-830.
[6] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut, 2021, 70(1): 9-29.
[7] Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology, 2020, 72(3): 1043-1055.
[8] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, 2018, 391(10138): 2417-2429.
[9] De Simone G, Di Masi A, Ascenzi P. Serum albumin: A multifaced enzyme. Int J Mol Sci, 2021, 22(18): 10086.
[10] Belinskaia DA, Voronina PA, Goncharov NV. Integrative role of albumin: Evolutionary, biochemical and pathophysiological aspects. J Evol Biochem Physiol, 2021, 57(6): 1419-1448.
[11] Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014, 60(6): 1851-1860.
[12] Xiao LL, Zhang F, Zhao YL, et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci Rep, 2020, 10(1): 18128.
[13] Das S, Maras JS, Hussain MS, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology, 2017, 65(2): 631-646.
[14] Rodriguez EL, Tao P, Woolfork AG, et al. Studies of binding by sulfonylureas with glyoxal- and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns. J Chromatogr A, 2021, 1638: 461683.
[15] Handy,Loscalzo J. The role of glutathione peroxidase-1 in health and disease. Free Radic Biol Med, 2022, 188: 146-161.
[16] Shevtsova A, Gordiienko I, Tkachenko V, et al. Ischemia-modified albumin: Origins and clinical implications. Dis Markers, 2021, 2021: 9945424.
[17] Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology, 2005, 41(6): 1211-1219.
[18] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications. Hepatology, 2021, 74(4): 2058-2073.
[19] Lee P, Wu X. Modifications of human serum albumin and their binding effect. Curr Pharm Des, 2015, 21(14): 1862-1865.
[20] Taverna M, Mira JP, Marie AL, et al. Specific antioxidant properties of human serum albumin. Ann Intensive Care, 2013, 3: 4.
[21] Baldassarre M, Domenicali M, Naldi M, et al. Albumin homodimers in patients with cirrhosis: Clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep, 2016, 6(1): 35987.
[22] Paar M, Fengler VH, Reibnegger G, et al. Determination of binding characteristics as a measure for effective albumin using different methods. Biochim Biophys Acta Gen Subj, 2023, 1867(9): 130427.
[23] Oettl K, Spinelboeck W, Dorn L, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol, 2013, 59(5): 978-983.
[24] Yavuz F, Biyik M, Asil M, et al. Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases. Turk J Med Sci, 2017, 47(3): 947-953.
[25] Volmer J, Arabi SH, Henning C, et al. Tuning human serum albumin (HSA) hydrogels through albumin glycation. Macromol Biosci, 2023, 23(3): e2200487.
[26] Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology, 2009, 50(2): 555-564.
[27] Brown KA, Melby JA, Roberts DS, et al. Top-down proteomics: challenges, innovations, and applications in basic and clinical research. Expert Rev Proteomics, 2020, 17(10): 719-733.
[28] Rahali MA, Lakis R, Sauvage FL, et al. Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis. J Chromatogr B Analyt Technol Biomed Life Sci, 2023, 1224: 123740.
[29] Tada S, Yasukawa K, Yatomi Y, et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin. Pract Lab Med, 2022, 31: e00281.
[30] Lakis R, Sauvage FL, Pinault E, et al. Semi-synthetic human albumin isoforms: Production, structure, binding capacities and influence on a routine laboratory test. Int J Biol Macromol, 2023: 126239.
[31] Tabata F, Wada Y, Kawakami S, et al. Serum albumin redox states: More than oxidative stress biomarker. Antioxidants (Basel), 2021, 10(4): 503.
[32] Nagumo K, Tanaka M, Chuang VT, et al. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS One, 2014, 9(1): e85216.
[33] Liu H, Ju A, Dong X, et al. Young and undamaged recombinant albumin alleviates T2DM by improving hepatic glycolysis through EGFR and protecting islet beta cells in mice. J Transl Med, 2023, 21(1): 89.
[34] Mori F, Natali L, Danesi R, et al. Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. Int J Biol Macromol, 2021, 183: 927-935.
[35] Tang J, Ju A, Li B, et al. Young and undamaged rMSA improves the healthspan and lifespan of mice. Biomolecules, 2021, 11(8): 1191. |
